TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells

(2013) R. N. Gunawardane et al.   MOLECULAR CANCER THERAPEUTICS

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model

(2012) S. Greenblatt et al.   BLOOD

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation

(2012) C. H. Man et al.   BLOOD

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity

(2012) C. Yao et al.   HUMAN MOLECULAR GENETICS

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

(2012) A B Williams et al.   LEUKEMIA

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

(2012) A S Moore et al.   LEUKEMIA

Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice

(2011) L. Li et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Further activation of FLT3 mutants by FLT3 ligand

(2011) R Zheng et al.   ONCOGENE

FLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations

(2011) A. T. Fathi et al.   ONCOLOGIST

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug resistance in mutant FLT3-positive AML

(2010) E Weisberg et al.   ONCOGENE

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute